
STERIS (STE) Stock Forecast & Price Target
STERIS (STE) Analyst Ratings
Bulls say
Steris is expected to see steady growth in all three segments, with potential for margin expansion as the company invests in new facilities and efficiency-enhancing technologies. The company's initial FY27 organic growth guidance of 6-7% and EPS guidance ahead of Street expectations show a strong outlook for the company. Furthermore, Steris is continuing to invest in capital allocation initiatives and has the potential for sustainable margin expansion of ~50 bps annually.
Bears say
Steris is highly reliant on its healthcare services segment for revenue, which brings in 70% of its total revenue. However, this segment is facing headwinds as demonstrated by the slower growth in capital equipment shipments and a backlog that has remained relatively stagnant. Despite a recent investment in a new facility, there are concerns about the company's ability to achieve strong efficiency gains and hit targeted ROIC levels within a reasonable timeframe. Additionally, the company's recent bolt-on acquisitions in its healthcare products segment may not contribute significant revenue, and we question the effectiveness of their new $1B share buyback program given their high leverage ratio and potential future investment needs.
This aggregate rating is based on analysts' research of STERIS and is not a guaranteed prediction by Public.com or investment advice.
STERIS (STE) Analyst Forecast & Price Prediction
Start investing in STERIS (STE)
Order type
Buy in
Order amount
Est. shares
0 shares